XML 50 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaborative Arrangements - Financial Information (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Sales $ 14,959 $ 13,154 $ 45,453 $ 35,183  
Cost of sales 3,934 3,450 13,530 9,752  
Selling, general and administrative 2,520 2,336 7,355 6,804  
Research and development 4,399 2,445 9,773 9,177  
Payables included in Accrued and other liabilities 22,998   22,998   $ 23,872
Other current assets | AstraZeneca | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Receivables included in Other current assets 290   290   271
Other current assets | Eisai | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Receivables included in Other current assets 202   202   200
Other current assets | Bayer AG | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Receivables included in Other current assets 144   144   114
Accounts Payable and Accrued Liabilities | AstraZeneca | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Payables included in Accrued and other liabilities 12   12   415
Accounts Payable and Accrued Liabilities | Eisai | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Payables included in Accrued and other liabilities 1   1   625
Accounts Payable and Accrued Liabilities | Bayer AG | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Payables included in Accrued and other liabilities 75   75   472
Accounts Payable and Accrued Liabilities | Ridgeback Biotherapeutics LP | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Payables included in Accrued and other liabilities 193   193   283
Other Noncurrent Liabilities | AstraZeneca | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Payables included in Other Noncurrent Liabilities 600   600   $ 0
Revenue | AstraZeneca | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Alliance revenue - profit sharing 294 252 868 741  
Revenue | AstraZeneca | Collaborative Arrangement | Alliance revenue - Lynparza          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Alliance revenue - profit sharing 284 246 825 721  
Revenue | AstraZeneca | Collaborative Arrangement | Alliance revenue - Koselugo          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Alliance revenue - profit sharing 10 6 43 20  
Revenue | Eisai | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Alliance revenue - profit sharing 202 188 660 498  
Revenue | Bayer AG | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Alliance revenue - profit sharing 88 100 258 248  
Sales 151 161 454 439  
Revenue | Bayer AG | Collaborative Arrangement | Adempas          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Net sales by Merck 57 59 181 188  
Revenue | Bayer AG | Collaborative Arrangement | Verquvo          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Net sales by Merck 6 2 15 3  
Revenue | Ridgeback Biotherapeutics LP | Collaborative Arrangement | Lagevrio          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Sales 436 0 4,859 0  
Cost of sales | AstraZeneca | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Cost of sales 64 42 425 125  
Amortization of intangible assets     250    
Cost of sales | Eisai | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Cost of sales 53 49 159 143  
Cost of sales | Bayer AG | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Cost of sales 55 53 158 328  
Amortization of intangible assets       153  
Cost of sales | Ridgeback Biotherapeutics LP | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Cost of sales 234 4 2,580 56  
Selling, general and administrative | AstraZeneca | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Selling, general and administrative 45 44 135 127  
Selling, general and administrative | Eisai | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Selling, general and administrative 42 34 115 88  
Selling, general and administrative | Bayer AG | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Selling, general and administrative 42 31 107 84  
Selling, general and administrative | Ridgeback Biotherapeutics LP | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Selling, general and administrative 41 6 105 13  
Research and development | AstraZeneca | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Research and development 28 27 79 87  
Research and development | Eisai | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Research and development 24 43 128 165  
Research and development | Bayer AG | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Research and development 18 16 52 36  
Research and development | Ridgeback Biotherapeutics LP | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Research and development $ 8 $ 58 $ 29 $ 167